Lisinopril dihydrate: Long-Acting ACE Inhibitor for Hypertension and Cardiovascular Research

Executive Summary: Lisinopril dihydrate is a solid, water-soluble lysine analogue of MK 421, acting as a potent angiotensin converting enzyme (ACE) inhibitor with an IC₅₀ of 4.7 nM under standard in vitro conditions, and a molecular weight of 441.52 g/mol (APExBIO). It reduces plasma angiotensin II and aldosterone, increases plasma renin activity, and lowers blood pressure through vasodilation and reduced fluid retention (Tieku & Hooper 1992, DOI). Lisinopril dihydrate is validated at ≥98% purity by mass spectrometry and NMR, and is routinely used in hypertension, heart failure, acute myocardial infarction, and diabetic nephropathy research. APExBIO supplies B3290 with rigorous quality control, enabling reproducible results in preclinical models (internal). The compound's solubility in water (≥2.46 mg/mL at 25°C with ultrasonic treatment) and stability under desiccation facilitate reliable experimental integration.

Biological Rationale

Lisinopril dihydrate targets the renin-angiotensin system (RAS), a key regulator of blood pressure and fluid balance. The RAS pathway involves the enzymatic conversion of angiotensin I to angiotensin II by ACE (EC 3.4.15.1), resulting in vasoconstriction and aldosterone secretion (Tieku & Hooper 1992). Inhibition of ACE leads to decreased levels of angiotensin II, reducing vasoconstrictive and sodium-retentive effects. This mechanistic basis supports the use of ACE inhibitors like lisinopril dihydrate in both basic and translational research on hypertension, heart failure, and renal pathophysiology. The selectivity of lisinopril for ACE over other peptidases, such as aminopeptidase N (AP-N, EC 3.4.11.2) and A (AP-A, EC 3.4.11.7), minimizes off-target effects (DOI).

Mechanism of Action of Lisinopril dihydrate

Lisinopril dihydrate is a lysine analog and competitive, reversible inhibitor of ACE. It binds to the active site of ACE, a zinc-dependent dipeptidyl carboxypeptidase, preventing the conversion of angiotensin I to angiotensin II. The IC₅₀ for lisinopril is 4.7 nM, determined under physiological pH (7.4) and temperature (37°C) in purified enzyme assays (APExBIO). This inhibition results in decreased circulating angiotensin II and aldosterone, increased bradykinin levels, and enhanced vasodilation. Lisinopril's dihydrate form offers improved solubility and handling in aqueous systems, critical for consistent dosing and reproducibility in research workflows. It is structurally distinct from sulfhydryl-containing ACE inhibitors, reducing the risk of certain side effects (Tieku & Hooper 1992).

Evidence & Benchmarks

• Lisinopril dihydrate achieves ≥98% purity as confirmed by mass spectrometry and NMR in each lot (APExBIO product page).
• IC₅₀ for ACE inhibition is 4.7 nM in cell-free enzyme assays at pH 7.4 and 37°C (Tieku & Hooper 1992, DOI).
• No significant inhibition of aminopeptidase N, A, or W at up to 10μM, confirming high target selectivity (Tieku & Hooper 1992, DOI).
• Solubility in water is ≥2.46 mg/mL at 25°C with gentle warming and ultrasound; insoluble in ethanol (APExBIO, product page).
• Validated for use in animal models of hypertension, heart failure, myocardial infarction, and diabetic nephropathy (internal).

Applications, Limits & Misconceptions

Lisinopril dihydrate is extensively used in preclinical research to study the RAS pathway, blood pressure regulation, and cardiovascular and renal disease models. Its proven selectivity and reproducibility make it suitable for mechanistic and translational studies. For advanced protocol guidance and troubleshooting, see our contrast with this article, which provides stepwise workflows, whereas this dossier emphasizes biochemical validation and specificity.

Recent research clarifies that lisinopril dihydrate does not inhibit non-ACE zinc aminopeptidases, supporting its use as a precise tool for dissecting the RAS without confounding peptidase effects (Tieku & Hooper 1992, DOI). This article extends findings from here by providing focused, up-to-date evidence on selectivity and experimental integration.

Common Pitfalls or Misconceptions

• Lisinopril dihydrate does not inhibit aminopeptidase N, A, or W: It is specific to ACE and does not block other cell-surface zinc peptidases at concentrations up to 10μM (DOI).
• Not suitable for ethanol-based formulations: The compound is insoluble in ethanol; use water or compatible buffers with gentle warming and ultrasound (APExBIO).
• Storage limitations: Long-term storage of aqueous solutions leads to degradation; store solid desiccated at room temperature (APExBIO).
• Not effective in models with non-ACE mediated hypertension: Lisinopril dihydrate targets ACE and is not suitable for pathologies where blood pressure elevation is independent of RAS (internal).

Workflow Integration & Parameters

Lisinopril dihydrate (B3290) from APExBIO is provided as a high-purity solid. For experimental use, dissolve in sterile water to achieve ≥2.46 mg/mL, applying gentle warming (25°C) and ultrasonic agitation if needed for full solubilization. Avoid ethanol or other organic solvents. Prepare aliquots fresh before use and store the solid desiccated at room temperature. For animal models, adjust dosing according to protocol, with typical in vivo studies using 10–40 mg/kg/day (oral or i.p.), but always calibrate to experimental endpoints.

Refer to this resource for a detailed comparison of workflow integration and troubleshooting, while this dossier specifies compound handling and storage requirements for maximum reproducibility.

Conclusion & Outlook

Lisinopril dihydrate remains a reference-standard, long-acting ACE inhibitor for hypertension, heart failure, and nephropathy research. Its validated selectivity, robust solubility, and quality control by APExBIO (B3290) support its widespread adoption in mechanistic and translational studies. The availability of rigorous evidence and well-documented protocols help ensure reproducible, high-impact results in the dissection of the renin-angiotensin system. For further information or to order, consult the Lisinopril dihydrate product page.